|
|
Blood, 15 October 2006, Vol. 108, No. 8, pp. 2755-2763.
Prepublished online as a Blood First Edition Paper on June 27, 2006; DOI 10.1182/blood-2006-02-005488.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
Wee J. Chng,
Roelandt F. Schop,
Tammy Price-Troska,
Irene Ghobrial,
Neil Kay,
Diane F. Jelinek,
Morie A. Gertz,
Angela Dispenzieri,
Martha Lacy,
Robert A. Kyle,
Philip R. Greipp,
Renee C. Tschumper,
Rafael Fonseca, and
Peter Leif Bergsagel
From the Department of Hematology-Oncology, Mayo Clinic Scottsdale, AZ; Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN; Dana Faber Cancer Institute, Boston, MA; Division of Internal Medicine, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN; Department of Immunology and Division of Hematology, Mayo Clinic College of Medicine, Mayo Graduate School, Rochester, MN.
Waldenström macroglobulinemia (WM) is a B-cell malignancy characterized by the ability of the B-cell clone to differentiate into plasma cells. Although the clinical syndrome and the pathologic characteristics are well defined, little is known about its biology and controversy still exists regarding its cell of origin. In this gene-expression study, we compared the transcription profiles of WM with those of other malignant B cells including (chronic lymphocytic leukemia [CLL] and multiple myeloma [MM]) as well as normal cells (peripheral-blood B cells and bone marrow plasma cells). We found that WM has a homogenous gene expression regardless of 6q deletion status and clusters with CLL and normal B cells on unsupervised clustering with very similar expression profiles. Only a small gene set has expression profiles unique to WM compared to CLL and MM. The most significantly up-regulated gene is IL6 and the most significantly associated pathway for this set of genes is MAPK signaling. Thus, IL6 and its downstream signaling may be of biologic importance in WM. Further elucidation of the role of IL-6 in WM is warranted as this may offer a potential therapeutic avenue.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Gene expression relates WM to CLL
- Adrian Wiestner
Blood 2006 108: 2499-2500.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. Poulain, I. Dervite, X. Leleu, V. Coiteux, P. Duthilleul, and P. Morel
The IL6(-174G/C) polymorphism is a prognostic factor for survival after treatment initiation in Waldenstrom macroglobulinemia patients aged 65 years or less
Haematologica,
July 1, 2008;
93(7):
1109 - 1111.
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Leleu, J. Eeckhoute, X. Jia, A. M. Roccaro, A.-S. Moreau, M. Farag, A. Sacco, H. T. Ngo, J. Runnels, M. R. Melhem, et al.
Targeting NF-{kappa}B in Waldenstrom macroglobulinemia
Blood,
May 15, 2008;
111(10):
5068 - 5077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lehto, M. I. Mayranpaa, T. Pellinen, P. Ihalmo, S. Lehtonen, P. T. Kovanen, P.-H. Groop, J. Ivaska, and V. M. Olkkonen
The R-Ras interaction partner ORP3 regulates cell adhesion
J. Cell Sci.,
March 1, 2008;
121(5):
695 - 705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Leleu, X. Jia, J. Runnels, H. T. Ngo, A.-S. Moreau, M. Farag, J. A. Spencer, C. M. Pitsillides, E. Hatjiharissi, A. Roccaro, et al.
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia
Blood,
December 15, 2007;
110(13):
4417 - 4426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trudel, Z. H. Li, J. Rauw, R. E. Tiedemann, X. Y. Wen, and A. K. Stewart
Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma
Blood,
June 15, 2007;
109(12):
5430 - 5438.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hatjiharissi, H. Ngo, A. A. Leontovich, X. Leleu, M. Timm, M. Melhem, D. George, G. Lu, J. Ghobrial, Y. Alsayed, et al.
Proteomic Analysis of Waldenstrom Macroglobulinemia
Cancer Res.,
April 15, 2007;
67(8):
3777 - 3784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Standal, N. Abildgaard, U.-M. Fagerli, B. Stordal, O. Hjertner, M. Borset, and A. Sundan
HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma
Blood,
April 1, 2007;
109(7):
3024 - 3030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Genetic Profile of Waldenstrom Macroglobulinemia
Journal Watch Oncology and Hematology,
November 27, 2006;
2006(1127):
1 - 1.
[Full Text]
|
|
|
| |
